Council of the
European Union

Brussels, 12 May 2016
(OR. en)

8840/16

CORDROGUE 21
SAN 180

COVER NOTE

From:	Matthias Ruete
date of receipt:	27 April 2016
To:	Ambassador Pieter de Gooijer
Subject:	Request for risk assessment on new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA)

Delegations will find attached a request from the Commission for a risk assessment on new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA).

EUROPEAN COMMISSION
DIRECTORATE-GENERAL MIGRATION and HOME AFFAIRS

The Director General

Brussels, 27 April 2016
DG HOME/D4/US/md/ ARES(2016)

Your Excellency,

On 16 April 2016, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol presented to the Council, the Commission and the European Medicines Agency a Joint Report on the new psychoactive substance MDMB-CHMICA. This Joint Report, drawn up in accordance with Article 5(1) of the Council Decision on the information exchange, risk assessment and control of new psychoactive substances[1], provides an overview of the available information on detections, patterns of use and incidents reported on this substance.

According to the Joint Report, a considerable number of serious adverse events associated with MDMB-CHMICA have been reported by eight Member States. This includes acute intoxications requiring hospitalisation and 29 deaths; in at least 12 cases MDMB-CHMICA appeared to be play a role in the death.

I therefore consider that the health and social risks posed by the manufacture, trafficking and use of MDMB CHMICA, as well as the involvement of organised crime and possible consequences of control measures, should be assessed through a risk assessment, as foreseen by Article 6 of the Council Decision 2005/387/JHA.

His Excellency
Ambassador Pieter de Gooijer
Permanent Representative of the Kingdom of the Netherlands to the European Union
4-10 Avenue de Cortenbergh
1040- Bruxelles
Belgium

[1] OJ L 127, 20.5.2005, p.32.

Commission européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË - Tel. +32 22991111

I should be grateful if you would notify this request to conduct risk assessment on MDMB-CHMICA to the Members of the Council and the Horizontal Drugs Group.

Yours faithfully,

Matthias RUETE

Annex 1: EMCDDA-Europol Joint report MDMB CHMICA, prepared in accordance with Article 5 of Council Decision 2005/387/JHA.

Annex 2: Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances.

Copy: Ms Christine Roger, Director-General, Secretariat General of the Council